Candesartan
- Generic Name
- Candesartan
- Brand Names
- Atacand, Atacand Hct
- Drug Type
- Small Molecule
- Chemical Formula
- C24H20N6O3
- CAS Number
- 139481-59-7
- Unique Ingredient Identifier
- S8Q36MD2XX
- Background
Candesartan is an angiotensin-receptor blocker (ARB) that may be used alone or with other agents to treat hypertension. It is available as a prodrug in the form of candesartan cilexetil.
- Indication
May be used as a first line agent to treat uncomplicated hypertension, isolated systolic hypertension and left ventricular hypertrophy. May be used as a first line agent to delay progression of diabetic nephropathy. Candesartan may be also used as a second line agent in the treatment of congestive heart failure, systolic dysfunction, myocardial infarction and coronary artery disease in those intolerant of ACE inhibitors.
- Associated Conditions
- Hypertension, NYHA Functional Class II-IV Heart Failure
Study to Compare the Safety and Pharmacokinetics of CKD-330 8/5mg With Coadministration of the Two Separate Drugs
- Conditions
- Hypertension
- Interventions
- First Posted Date
- 2015-09-14
- Last Posted Date
- 2015-12-07
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 53
- Registration Number
- NCT02548286
- Locations
- 🇰🇷
Chungnam National University Hospital, Daejeon, Jung-gu, Korea, Republic of
Efficacy and Safety of Candesartan Associated With Chlorthalidone in Essential Arterial Hypertension Control
- Conditions
- Essential Arterial Hypertension
- Interventions
- Drug: losartan+hydrochlorothiazide
Efficacy and Safety of Candesartan Associated With Chlorthalidone Versus Losartan Associated With Hydrochlorothiazide (Hyzaar®) in Essential Hypertension Control
- Conditions
- Essential Arterial Hypertension
- Interventions
- Drug: Losartan+hydrochlorothiazide
A Study to Evaluate the Efficacy and Safety of Amlodipine Besylate and Candesartan Cilexetil in Essential Hypertension Patient Who Are Not Adequately Controlled With Candesartan Cilexetil Monotherapy
- Conditions
- Essential Hypertension
- Interventions
- First Posted Date
- 2015-02-23
- Last Posted Date
- 2023-05-06
- Lead Sponsor
- HK inno.N Corporation
- Target Recruit Count
- 181
- Registration Number
- NCT02368652
- Locations
- 🇰🇷
Inje University Haeundae Baik Hospital, Busan, Korea, Republic of
🇰🇷Hallym University Sungsim Hospital, Anyang-si, Korea, Republic of
🇰🇷Chonnam National University Hospital, Gwangju, Korea, Republic of
A Phase 2 Dose-finding Study of TAK-272 in Participants With Type 2 Diabetes Mellitus and Microalbuminuria
- Conditions
- Type 2 Diabetes Mellitus and Microalbuminuria
- Interventions
- First Posted Date
- 2015-01-07
- Last Posted Date
- 2018-08-13
- Lead Sponsor
- Takeda
- Target Recruit Count
- 415
- Registration Number
- NCT02332824
Study to Assess Potential Different Properties of Telmisartan Compared to Candesartan in Healthy Volunteers
- First Posted Date
- 2014-10-10
- Last Posted Date
- 2014-10-10
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 24
- Registration Number
- NCT02261116
Relative Bioavailability Study of Candesartan Cilexetil Under Fasting Conditions
- Conditions
- Cardiovascular Disease
- Interventions
- First Posted Date
- 2014-10-01
- Last Posted Date
- 2018-03-12
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 18
- Registration Number
- NCT02254447
- Locations
- 🇮🇳
GSK Investigational Site, Hyderabad, India
Candesartan Cilexetil Special Drug Use Surveillance 「Challenge - Quality Control」
- First Posted Date
- 2014-08-07
- Last Posted Date
- 2018-11-05
- Lead Sponsor
- Takeda
- Target Recruit Count
- 18113
- Registration Number
- NCT02211638
A Dose Selection Trial of CKD-330 in Patients With Essential Hypertension
- Conditions
- Essential Hypertension
- Interventions
- First Posted Date
- 2014-08-01
- Last Posted Date
- 2015-03-30
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 456
- Registration Number
- NCT02206165
- Locations
- 🇰🇷
Seoul National University Bundang Hospital, Seongnam, Korea, Republic of
Bioequivalence Study (Candesartan 8 mg and Amlodipine 5 mg)
- Conditions
- Hypertension
- Interventions
- Drug: CKD-330 8/5mg
- First Posted Date
- 2014-07-10
- Last Posted Date
- 2014-12-02
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 32
- Registration Number
- NCT02186496
- Locations
- 🇰🇷
Chungnam National University Hospital, Daejeon, Chungcheongbuk-do, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.